It's important to note others are enriching for BRCA status.
Myriad and Abbott Enter Into Cooperative Agreement
Myriad Will Assess BRCA Status in Phase III Study
SALT LAKE CITY, Oct 26, 2010 (GlobeNewswire via COMTEX News Network) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that it has signed an agreement with Abbott Laboratories, a global health care company, to conduct BRCA1 and BRCA2 mutation testing on patients to be enrolled in a Phase III multi-center, multi-national clinical study (the "Study") of a novel drug candidate (the "Study Drug") for the treatment of metastatic breast cancer. This agreement is in addition to a similar previous agreement for a Phase II study with the same Study Drug.
Under the agreement, Myriad will use its BRACAnalysis(R) test to identify the presence of germline mutations in the breast cancer patients to be enrolled in the Study. Myriad will determine the mutation status of these patients and will provide standard test reports to the clinicians at each study site.
"We are extremely pleased to be working with Abbott, one of the world's leading healthcare companies, on this exciting new clinical study to find better, more effective treatments for patients suffering from breast cancer," said Peter Meldrum, President and Chief Executive Officer of Myriad Genetics, Inc. "This collaboration is a further demonstration of Myriad's commitment to and leadership in the field of companion diagnostics."
About BRACAnalysis(R)
BRACAnalysis is an analysis of the BRCA1 and BRCA2 genes developed by Myriad Genetics for assessing a woman's risk for hereditary breast and ovarian cancer. A woman who tests positive with the BRACAnalysis test has, on average, an 82% risk of developing breast cancer during her lifetime and a 44% risk of developing ovarian cancer. BRACAnalysis provides important information that the Company believes will help patients and their physicians make better informed lifestyle, surveillance, preventive medication and treatment decisions. As published in the Journal of the National Cancer Institute, researchers have shown that pre-symptomatic individuals who have a high risk of developing breast cancer can reduce their risk by approximately 50% with appropriate preventive therapies. Additionally, as published in the New England Journal of Medicine, researchers have shown that pre-symptomatic individuals who carry gene mutations can lower their risk of developing ovarian cancer by approximately 60% with appropriate preventive therapies.
News 
Market Data 
Discover 
AI
